BOSTON, May 05, 2009 (BUSINESS WIRE) -- Orthofix International N.V. (NASDAQ: OFIX) (the Company) announced today
that the Company has begun the limited market release of Trinity(R)
Evolution(TM) in collaboration with the Musculoskeletal
Transplant Foundation (MTF). Trinity Evolution is a stem cell-based bone
growth matrix designed to advance the surgical use of allografts by
providing characteristics similar to an autograft in spinal and
orthopedic procedures.
"We are extremely pleased to announce that we have begun to make Trinity
Evolution available to our surgeon customers. The initial feedback we
have received on Trinity Evolution has been extraordinarily positive,
and we look forward to our full market release by July 1, 2009," said
Alan Milinazzo, President and CEO of Orthofix International.
Dr. Steve Yocom completed the first procedure using Trinity Evolution on
April 28th. The 46-year-old patient underwent a lumbar spine
fusion procedure at Cooper University Hospital in Camden, NJ. Since
commencing our limited release, Trinity Evolution has been implanted in
a variety of spinal and orthopedic procedures by several leading
surgeons around the country, including Dr. Michael Zindrick, Dr. Mark
Lorenz, Dr. Christopher Bibbo, Dr. Daniel Lee and Dr. Jamie Gottlieb.
"Trinity Evolution is an excellent new tissue form that should be of
great benefit to patients and the doctors who serve them," said Bruce
Stroever, President and CEO of MTF.
Trinity Evolution is used by surgeons to facilitate bone fusion, and
will be marketed exclusively by Orthofix Spinal Implants and Orthofix
Orthopedics. MTF is responsible for the recovery of donor tissue, the
processing of the bone growth matrix, and for the fulfilment of orders
received.
Orthofix anticipates completing the full market release of Trinity
Evolution by July 1st of this year.
About Orthofix
Orthofix International, N.V., a global medical device company, offers a
broad line of minimally invasive surgical, and non-surgical, products
for the spine, orthopedic, and sports medicine market sectors that
address the lifelong bone-and-joint health needs of patients of all
ages-helping them achieve a more active and mobile lifestyle. Orthofix's
products are widely distributed around the world to orthopedic surgeons
and patients via Orthofix's sales representatives and its subsidiaries,
including BREG, Inc. and Blackstone Medical, Inc., and via partnerships
with other leading orthopedic product companies. In addition, Orthofix
is collaborating in R&D partnerships with leading medical institutions
such as the Musculoskeletal Transplant Foundation, the Orthopedic
Research and Education Foundation, Rutgers University, Texas Scottish
Rite Hospital for Children and National Osteoporosis Institute. For more
information about Orthofix, please visit www.orthofix.com.
Forward-Looking Statements
This communication contains certain forward-looking statements under the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements, which may include, but are not limited to, statements
concerning the projections, financial condition, results of operations
and businesses of Orthofix and its subsidiaries and are based on
management's current expectations and estimates and involve risks and
uncertainties that could cause actual results or outcomes to differ
materially from those contemplated by the forward-looking statements.
Factors that could cause or contribute to such differences may include,
but are not limited to, risks relating to the expected sales of its
products, including recently launched products, unanticipated
expenditures, changing relationships with customers, suppliers and
strategic partners, risks relating to the protection of intellectual
property, changes to the reimbursement policies of third parties,
changes to and interpretation of governmental regulation of medical
devices, the impact of competitive products, changes to the competitive
environment, the acceptance of new products in the market, conditions of
the orthopedic industry and the economy, corporate development and
market development activities, including acquisitions or divestitures,
unexpected costs or operating unit performance related to recent
acquisitions and other factors described in our annual report on Form
10-K and other periodic reports filed by the Company with the Securities
and Exchange Commission.
SOURCE: Orthofix International, N.V.
Orthofix International, N.V.
Dan Yarbrough, 617-912-2903
Vice President of Investor Relations
danyarbrough@orthofix.com
Copyright Business Wire 2009